| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
BRAF Mutation Analysis, ASO
Test Code90868
CPT Codes
81210<br /> ** This test is not available for New York patient testing **
Preferred Specimen
Paraffin-embedded tissue
Transport Temperature
Room temperature
Specimen Stability
Room temperature: Indefinite
Refrigerated: Indefinite
Frozen: Do Not Freeze
Refrigerated: Indefinite
Frozen: Do Not Freeze
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Baked slides
Methodology
Allele-Specific Real-Time Polymerase Chain Reaction
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics . It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Tues, Sat; Report available: 4-7 days
Clinical Significance
This BRAF Mutation Analysis, ASO test can be used to help
select melanoma patients who are more likely to respond to
treatment with vemurafenib. Vemurafenib is not recommended
for use in patients with wild type BRAF.
select melanoma patients who are more likely to respond to
treatment with vemurafenib. Vemurafenib is not recommended
for use in patients with wild type BRAF.
